CMS Issues Request for Information on Electronic Prescribing of Controlled Substances; President Trump Signed Executive Orders on Drug Pricing; AMCP Submits Comments on Medicaid Drug Rebate Program Proposed Rule; House of Representatives Holds COVID-19 Vaccine and Coronavirus Response Hearings.
CMS Issues Proposed Rule Updating the Medicaid Drug Rebate Program; SAMHSA Publishes Final Rule Amending Substance Use Disorder Treatment Records Privacy; AMCP Joins Pharmacy Stakeholder Letter on Vaccine Administration; AMCP Signs Joint Comment Letter on Pharmacy Telehealth in Medicare.
AMCP Joins Pharmaceutical Supply Chain Stakeholders to Support Access to Medications; AMCP Comments on COVID-19 Changes to Medicare Program; FDA Issues RFI on Improving the Orange Book; CMS Issues Final Medicare Part C and Part D Policy, Technical Rule
May issue includes: AMCP Submits Comments on Proposed Part D MTM Program CMR Changes; AMCP Submits Comments on Proposed Part D MTM Program CMR Changes; Two Proposed Biosimilars Bills Fail to Advance
April issue includes: CARES Act Includes Changes Relevant to Managed Care Pharmacy, Substance Abuse Record Rules; HHS Authorizes Pharmacists to Order and Administer COVID19 Tests; AMCP Launches COVID19 Resource Center; AMCP Submits Comments on Proposed Medicare Advantage and Part D Rule; AMCP Comments to FDA and FTC on a Competitive Biosimilar Marketplace
March 2020 Legislative & Regulatory Briefing: Articles include CMS Issues Contract Year 2021 and 2022 Medicare Advantage and Part D Proposed Rule; AMCP Shares CMS Resources for COVID-19 Response; AMCP Submits Comments on Drug Importation on Proposals
AMCP Develops 2020 Policy and Advocacy Focus Areas; CMS Issues CY 2021 Advanced Notice for MA Capitation Rates and Part C and Part D Payment Policies – Part II; CMS Issues CY 2021 and 2022 Medicare Advantage and Part D Proposed Rule; CMS Releases New Guidance on Medicaid Waiver Flexibility